ECE2022 Poster Presentations Diabetes, Obesity, Metabolism and Nutrition (202 abstracts)
REAL Life study of SEMaglutide in Patients with Type 2 diabetes in SPain (REALSEM-SP): Retrospective clinical study on the efficacy, adherence, and safety with Semaglutide
Jersy Jair Cardenas Salas 1,2 , Roberto Miguel Sierra Poyatos 3,4 , Bogdana Luiza Luca 3 , Begoña Sánchez Lechuga 3 , Naiara Modroño Mostoles 2 , Teresae Montoya Alvarez 2 , María De La Paz GóMez Montes 2 , Raquel Sanchez-Lopez 3 , Carlos Casado 3 & Clotilde Vazquez Martinez 2,3,4
1Hospital Universitario Fundación Jimánez Díaz, Endocrinology, Madrid, Spain; 2Hospital Universitario Infanta Elena, Spain; 3Hospital Universitario Fundación Jimánez Díaz, Madrid, Spain; 4General Hospital Villalba, Spain
Introduction: Real-world data on glucose and weight control effectiveness in patients with Type 2 diabetes mellitus (T2DM) on treatment with semaglutide is scarce. We aim to assess it in a cohort of patients from a real-world setting in Spain.
Materials and methods: We identified 830 patients with T2DM that were prescribed Semaglutide once-weekly since May 2019 to December 2020, in 4 hospitals in Madrid-Spain. At 6±3 months, 435 GPL1-naïve and 317 GLP1-experienced patients continued on treatment. Semaglutide withdrawal ocurred in 78 patients(9.4%), mainly due to gastrointestinal adverse events. At 12±3 months, 317 GPL1-naïve and 265 GLP1-experienced patients continued on treatment. Semaglutide withdrawal ocurred in 24 patients (3.3%), mainly due to gastrointestinal adverse events. The changes in HbA1c, weight, fat-mass and skeletal-muscle-mass at 6 and 12 months of follow up, adjusted by basal HbA1c, age, T2DM duration, BMI, sex, and change in Metformin, DPP-4, SGLT-2, Sulfonylurea, Repaglinide, Insuline and Thiazolidinedione status was assessed (multiple linear regression model).
Results: Baseline characteristics and T2DM treatments are shown in Table 1. There was a significant reduction in HbA1c, weight, and fat mass after Semaglutide treatment at 6 and 12 months of follow-up (Table 2). The proportion of patients that achieved a HbA1c ≤7% was significant higher in boths groups. After adjusment the baseline-HbA1c was the only predictor for HbA1c change at 6 and 12 months.
| GLP1-naïve | GLP1-experienced | |
| Male: (%) | 55.6 | 56.8 |
| Age: (years) | 59.6(10.5) | 61.3(9.1) |
| T2DM duration(years) | 9.0(7.5) | 11.3(6.8) |
| Weight: (kg) | 99.9(19.3) | 98.2(16.2) |
| BMI: (kg/m2) | 36.4(5.5) | 35.6(5.4) |
| Baseline-HbA1c | 7.8(1.5) | 7.3(1.2) |
| Baseline-eFGR(ml/min1.73 m2) | 85.9(20.8) | 82.9(20.1) |
| HbA1c ≤7% | 36.6 | 43.9 |
| T2DM-treatment(%) -Metformin -DPP-4 inhibitor -SGLT2 inhibitor -Sulfonylurea -Repaglinide -Insuline -Thiazolidinediona -GLP1 agonist | 82.8 40.7 31.5 9.9 7.4 31.5 0.6 0 | 91.1 2.2 48.9 5.7 11.4 42.6 0.6 100 (SD) |
| GLP1-naïve | GLP1-experienced | ||||
| 6 m | 12 m | 6 m | 12 m | ||
| HbA1c change | Total | -1,24** | -1.22** | -0.42** | -0.32** |
| <0.5 mg | -1.18** | -1.14** | -0.34** | +0.01 | |
| 1.0 mg | -1.42** | -1.29** | -0.49** | -0.40** | |
| Weight Change (%) | Total | -4.93** | -6.71** | -1.92** | -3.06** |
| <0.5 mg | -4.71** | -6.49** | -1.05** | -2.03** | |
| 1.0 mg | -5.70** | -6.90** | -2.72** | -3.30** | |
| % with HbA1c ≤7% | 70.85** | 74.75** | 62.69** | 62.86** | |
| % with Weight loss ≥5% | 44.3** | 55** | 18.3** | 33.1** | |
| % with Weight loss ≥10% | 14.8** | 26.3** | 5.1* | 8.3** | |
| Fat mass(%) change | -2.02** | -3.1** | -0.27* | -0.93* | |
| Skeletal muscle mass(kg) change | -0.48** | -0.89** | -0.47* | -0.53* | |
| ** P<0.01; * P<0.05; m = months | |||||
Conclusion: Treatment with semaglutide once-weekly is an effective glucose and weight lowering treatment in GLP1-naïve and GLP1-experienced patients with T2DM.
Article tools
My recent searches
My recently viewed abstracts
Authors
Endocrine Abstracts
ISSN 1470-3947 (print) | ISSN 1479-6848 (online)
© Bioscientifica 2024 |
Privacy policy |
Cookie settings
BiosciAbstracts
Bioscientifica Abstracts is the gateway to a series of products that provide a permanent, citable record of abstracts for biomedical and life science conferences.
Find out more